|  |  |
| --- | --- |
| **Complete Descriptive Statistics in the National Cancer Database; Frequency Tables** | |
| **Variable (Number Observed)** | **Value(N, %)\*** |
| **Age in years (180,150)** | 64.83 ± 11.17 |
| **Sex (180,150)** |  |
| Male | 92,747 (51) |
| Female | 87,403 (49) |
| **Race (180,150)** |  |
| American Indian or Eskimo | 572 (0.3) |
| Asian | 5,210 (2.9) |
| Black | 20,895 (11.6) |
| Other | 1,301 (0.7) |
| Pacific Islander | 361 (0.2) |
| Unknown | 1,362 (0.8) |
| White | 150,458 (84) |
| **Spanish or Hispanic Origin (180,150)** |  |
| No | 168,001 (93) |
| Unknown | 4,999 (2.8) |
| Yes | 7,140 (3.9) |
| **Median Income in $ adjusted for 2016 inflation (180,150)** |  |
| Less $30,000 | 35,206 (20) |
| $30,000 to 34,999 | 39,200 (22) |
| $35,000 to 45,999 | 38,911 (22) |
| Above $46,000 | 51,040 (28) |
| **No high school degree % against 2016 (180,150)** |  |
| Less 6.3% | 34,020 (19) |
| 6.3% to 10.8% | 46,036 (26) |
| 10.9% to 17.6% | 46,857 (26) |
| Above 17.6% | 37,784 (21) |
| **Urban or rural area (180,150)** |  |
| Metro | 143,965 (80) |
| Urban | 27,683 (15) |
| Rural | 3,763 (2) |
| **Year of Diagnosis (180,150)** | (2010-2018) |
| **Facility Type (180,150)** |  |
| Academic | 59,579 (33) |
| Community Cancer Program | 12,998 (7) |
| Comprehensive Community Cancer Program | 68,849 (38) |
| Integrated Cancer Program | 35,478 (20) |
| **Facility Location (180,150)** |  |
| East North Central | 32,525 (18) |
| East South Central | 14,524 (8) |
| Middle Atlantic | 22,226 (15) |
| Mountain | 7,025 (3.9) |
| New England | 10,696 (5.9) |
| Pacific | 18,980 (11) |
| South Atlantic | 38,818 (22) |
| West North Central | 13,761 (7.6) |
| West South Central | 14,549 (8.1) |
| **Great Circle Distance in miles (180,150)** | 29.13 ± 106.87 |
| **Total Charlson-Deyo Score (180,150)** |  |
| 0 | 116,058 (64) |
| 1 | 40,727 (23) |
| 2 | 14,759 (8.2) |
| 3 | 8,570 (4.8) |
| **Detailed Anatomic Site (180,150)** |  |
| Adrenal gland, NOD | 2 (0) |
| Anal canal | 24 (0) |
| Anus, NOS | 17 (0) |
| Appendix | 14 (0) |
| Autonomic NS, NOS | 6 (0) |
| Bile duct, extrahepatic | 58 (0) |
| Bile duct, intrahepatic | 108 (0.1) |
| Biliary, NOS | 43 (0) |
| Biliary, overlapping | 4 (0) |
| Bladder, anterior wall | 13 (0) |
| Bladder, dome | 22 (0) |
| Bladder, lateral wall | 62 (0) |
| Bladder, neck | 10 (0) |
| Bladder, NOS | 302 (0.2) |
| Bladder, overlapping | 65 (0) |
| Bladder, posterior wall | 24 (0) |
| Bladder, trigone | 17 (0) |
| Bone marrow | 18 (0) |
| Bone, NOS | 14 (0) |
| Bones, overlapping | 1 (0) |
| Bones, pelvis sacrum and coccyx | 17 (0) |
| Bones, skull, and face | 15 (0) |
| Breast, axillary tail | 57 (0) |
| Breast, central | 280 (0.2) |
| Breast, lower inner quadrant | 179 (0.1) |
| Breast, lower outer quadrant | 315 (0.2) |
| Breast, nipple | 32 (0) |
| Breast, NOS | 3137 (1.7) |
| Breast, overlapping | 1291 (0.7) |
| Breast, upper inner quadrant | 351 (0.2) |
| Breast, upper outer quadrant | 1437 (0.8) |
| Bronchus, main | 7178 (4) |
| Cardia, NOS | 521 (0.3) |
| Cecum | 382 (0.2) |
| Cervix uteri | 270 (0.1) |
| Cervix uteri, overlapping | 10 (0) |
| Ciliary body | 2 (0) |
| Cloacogenic zone | 1 (0) |
| Colon, ascending | 319 (0.2) |
| Colon, descending | 79 (0) |
| Colon, hepatic flexure | 89 (0) |
| Colon, NOS | 507 (0.3) |
| Colon, overlapping | 34 (0) |
| Colon, sigmoid | 427 (0.2) |
| Colon, splenic flexure | 37 (0) |
| Colon, transverse | 111 (0.1) |
| Conjunctiva | 2 (0) |
| Corpus uteri | 41 (0) |
| Corpus uteri, overlapping | 3 (0) |
| Digestive, overlapping | 28 (0) |
| Duodenum | 52 (0) |
| Ear, external | 41 (0) |
| Ear, middle | 6 (0) |
| Endocervix | 37 (0) |
| Endometrium | 603 (0.3) |
| Esophagus, abdominal | 9 (0) |
| Esophagus, cervical | 5 (0) |
| Esophagus, lower third | 1242 (0.7) |
| Esophagus, middle third | 198 (0.1) |
| Esophagus, NOS | 336 (0.2) |
| Esophagus, overlapping | 138 (0.1) |
| Esophagus, thoracic | 55 (0) |
| Esophagus, upper third | 45 (0) |
| Exocervix | 1 (0) |
| Eye, NOS | 3 (0) |
| Eyelid | 3 (0) |
| Fallopian tube | 7 (0) |
| Female genitals, NOS | 50 (0) |
| Female genitals, other | 2 (0) |
| Female genitals, overlapping | 6 (0) |
| Fundus uteri | 8 (0) |
| Gallbladder | 88 (0) |
| Gastric andrum | 43 (0) |
| Gastrointestinal, NOS | 357 (0.2) |
| Glottis | 5 (0) |
| Heart | 38 (0) |
| Heart mediastinum, overlapping | 1 (0) |
| Ileum | 18 (0) |
| Intestinal tract, NOS | 10 (0) |
| Isthmus uteri | 3 (0) |
| Jejunum | 18 (0) |
| Kidney, NOS | 5011 (2.8) |
| Lacrimal gland | 1 (0) |
| Langerhans, islets | 2 (0) |
| Larynx, NOS | 19 (0) |
| Limb bone, NOS | 5 (0) |
| Lip, NOS | 8 (0) |
| Liver | 507 (0.3) |
| Long bones and lower limb | 22 (0) |
| Long bones and upper limb, scapula | 6 (0) |
| Lung, lower lobe | 34356 (19.1) |
| Lung, middle lobe | 5600 (3.1) |
| Lung, NOS | 24601 (13.7) |
| Lung, overlapping | 2075 (1.2) |
| Lung, upper lobe | 73889 (41) |
| Lymph nodes, axilla, and arm | 11 (0) |
| Lymph nodes, head face and neck | 24 (0) |
| Lymph nodes, inguinal | 7 (0) |
| Lymph nodes, intraabdominal | 36 (0) |
| Lymph nodes, intrathoracic | 7 (0) |
| Lymph nodes, multiple | 179 (0.1) |
| Lymph nodes, NOS | 233 (0.1) |
| Lymph nodes, pelvis | 9 (0) |
| Mandible | 3 (0) |
| Mediastinum, anterior | 17 (0) |
| Mediastinum, NOS | 39 (0) |
| Mediastinum, posterior | 3 (0) |
| Myometrium | 7 (0) |
| Nasal cavity | 65 (0) |
| Nasopharynx, NOS | 4 (0) |
| Nasopharynx, overlapping | 1 (0) |
| Orbit, NOS | 8 (0) |
| Oropharynx, overlapping | 1 (0) |
| Ovary | 259 (0.1) |
| Pancreas, body | 144 (0.1) |
| Pancreas, head | 352 (0.2) |
| Pancreas, NOS | 368 (0.2) |
| Pancreas, other | 15 (0) |
| Pancreas, overlapping | 89 (0) |
| Pancreas, tail | 208 (0.1) |
| Pancreatic duct | 1 (0) |
| Parotid gland | 1 (0) |
| Pelvis, NOS | 1 (0) |
| Peripheral and autonomic NS, thorax | 3 (0) |
| Peripheral and autonomic NS, trunk NOS | 1 (0) |
| Peritoneum, NOS | 1 (0) |
| Placenta | 23 (0) |
| Pleura, NOS | 1 (0) |
| Prostate gland | 720 (0.4) |
| Pylorus | 5 (0) |
| Rectosigmoid junction | 230 (0.1) |
| Rectum anus and anal canal, overlapping | 22 (0) |
| Rectum, NOS | 581 (0.3) |
| Renal pelvis | 101 (0.1) |
| Respiratory and intrathoracic, overlapping | 2 (0) |
| Respiratory, illdefined | 1 (0) |
| Retroperitoneum | 4 (0) |
| Rib sternum and clavicle | 4 (0) |
| Sinus, ethmoid | 18 (0) |
| Sinus, frontal | 5 (0) |
| Sinus, maxillary | 34 (0) |
| Sinus, NOS | 16 (0) |
| Sinus, overlapping | 4 (0) |
| Sinus, sphenoid | 10 (0) |
| Skin, face other | 134 (0.1) |
| Skin, lower limb | 241 (0.1) |
| Skin, NOS | 5259 (2.9) |
| Skin, overlapping | 11 (0) |
| Skin, scalp, and neck | 236 (0.1) |
| Skin, trunk | 719 (0.4) |
| Skin, upper limb | 315 (0.2) |
| Small intestine, NOS | 54 (0) |
| Soft tissues, abdomen | 32 (0) |
| Soft tissues, head face and neck | 57 (0) |
| Soft tissues, lower limb | 106 (0.1) |
| Soft tissues, NOS | 111 (0.1) |
| Soft tissues, overlapping | 2 (0) |
| Soft tissues, pelvis | 50 (0) |
| Soft tissues, thorax | 83 (0) |
| Soft tissues, trunk NOS | 16 (0) |
| Soft tissues, upper limb | 23 (0) |
| Spleen | 5 (0) |
| Stomach, body | 61 (0) |
| Stomach, fundus | 35 (0) |
| Stomach, greater curvature NOS | 28 (0) |
| Stomach, lesser curvature NOS | 23 (0) |
| Stomach, NOS | 197 (0.1) |
| Stomach, overlapping | 48 (0) |
| Subglottis | 1 (0) |
| Supraglottis | 32 (0) |
| Testis, descended | 139 (0.1) |
| Testis, NOS | 400 (0.2) |
| Testis, undescended | 13 (0) |
| Thorax, NOS | 1 (0) |
| Thyroid gland | 3 (0) |
| Tongue, base NOS | 1 (0) |
| Tonsil, NOS | 3 (0) |
| Tonsillar pillar | 1 (0) |
| Trachea | 12 (0) |
| Unknown | 21 (0) |
| Urachus | 3 (0) |
| Ureter | 43 (0) |
| Ureteric orifice | 2 (0) |
| Urethra | 12 (0) |
| Urinary, NOS | 47 (0) |
| Urinary, overlapping | 1 (0) |
| Uterine adnexa | 1 (0) |
| Uterus, NOS | 162 (0.1) |
| Vater, ampulla | 12 (0) |
| Vertebral column | 10 (0) |
| **Laterality (180,150)** |  |
| Not paired | 24,812 (14) |
| Paired, bilateral | 3,313 (1.8) |
| Paired, left | 61,437 (34) |
| Paired, midline | 120 (0.1) |
| Paired, not specified | 8,884 (4.9) |
| Paired, right | 81,165 (45) |
| Right or left, not specified | 419 (0.2) |
| **ICD-O Morphology/Histology (180,150)** |  |
| Acinar cell carcinoma | 482 (0.3) |
| Acinar cell cystadenocarcinoma | 98 (0.1) |
| Adenocarcinomas, other | 79073 (43.9) |
| Adenosquamous carcinoma | 1456 (0.8) |
| Adnexal and skin appendage neoplasms | 26 (0) |
| Atypical carcinoid tumor | 108 (0.1) |
| Basal cell carcinomas, other | 1 (0) |
| Basaloid squamous cell carcinoma | 104 (0.1) |
| Blood vessel tumors, other | 13 (0) |
| Carcinoid tumor, NOS | 182 (0.1) |
| Carcinoma, other | 8146 (4.5) |
| Carcinoma, undifferentiated, NOS | 97 (0.1) |
| Carcinosarcoma, NOS | 111 (0.1) |
| Cholangiocarcinoma | 168 (0.1) |
| Choriocarcinoma, NOS | 46 (0) |
| Clear cell adenocarcinoma, NOS | 2097 (1.2) |
| CNS embryonal tumor, NOS | 3 (0) |
| Combined small cell carcinoma | 477 (0.3) |
| Complex epithelial neoplasms | 45 (0) |
| Complex mixed and stromal neoplasms | 60 (0) |
| Cystic, mucinous and serous carcinomas | 41 (0) |
| Ductal and lobular carcinomas, other | 57 (0) |
| Endometrioid adenocarcinoma, NOS | 276 (0.2) |
| Ewing sarcoma | 39 (0) |
| Fibroepithelial neoplasms | 6 (0) |
| Fibromatous neoplasms | 34 (0) |
| Germ cell neoplasms | 11 (0) |
| Giant cell tumors | 2 (0) |
| Granular cell tumors and alveolar soft part sarcomas | 22 (0) |
| Hemangiosarcoma | 105 (0.1) |
| Hepatocellular carcinoma, all types | 439 (0.2) |
| Hepatoid adenocarcinoma | 41 (0) |
| Infiltrating duct and lobular carcinoma | 181 (0.1) |
| Infiltrating duct carcinoma, NOS | 4526 (2.5) |
| Infiltrating duct mixed with other types of carcinoma | 84 (0) |
| Inflammatory carcinoma | 122 (0.1) |
| Large cell carcinoma, NOS | 1101 (0.6) |
| Large cell neuroendocrine carcinoma | 1820 (1) |
| Leiomyosarcoma, NOS | 108 (0.1) |
| Lepidic adenocarcinoma | 249 (0.1) |
| Leukemias, other | 19 (0) |
| Lipomatous sarcomas | 23 (0) |
| Lobular carcinoma, NOS | 439 (0.2) |
| Lymphoid leukemias | 6 (0) |
| Malignant lymphoma, diffuse | 15 (0) |
| Malignant lymphoma, large B-cell, diffuse, NOS | 440 (0.2) |
| Malignant lymphoma, non-Hodgkin, NOS | 55 (0) |
| Malignant melanoma, NOS | 6350 (3.5) |
| Malignant peripheral nerve sheath tumor | 18 (0) |
| Malignant tumor, NOS | 25 (0) |
| Mature B-cell lymphomas, other | 114 (0.1) |
| Mature T- and NK-cell lymphomas | 35 (0) |
| Melanoma, other | 243 (0.1) |
| Miscellaneous tumors, other | 3 (0) |
| Mixed cell adenocarcinoma | 72 (0) |
| Mucin-producing adenocarcinoma | 251 (0.1) |
| Mucinous adenocarcinoma | 966 (0.5) |
| Mucoepidermoid carcinoma | 15 (0) |
| Mullerian mixed tumor | 37 (0) |
| Myomatous neoplasms, other | 36 (0) |
| Myxomatous neoplasms | 2 (0) |
| Neoplasm, malignant | 5459 (3) |
| Neuroendocrine carcinoma, NOS | 2988 (1.7) |
| Neuroepitheliomatous neoplasms | 16 (0) |
| Nodular melanoma | 367 (0.2) |
| Non-small cell carcinoma | 12511 (6.9) |
| Oat cell carcinoma | 102 (0.1) |
| Osseous and chondromatous neoplasms | 46 (0) |
| Papillary adenocarcinoma, NOS | 737 (0.4) |
| Papillary carcinoma, NOS | 65 (0) |
| Papillary transitional cell carcinoma | 114 (0.1) |
| Paragangliomas and glomus tumors | 2 (0) |
| Plasma cell tumors | 5 (0) |
| Pleomorphic carcinoma | 148 (0.1) |
| Pseudosarcomatous carcinoma | 532 (0.3) |
| Renal cell carcinoma, NOS | 2257 (1.3) |
| Renal cell carcinoma, other | 25 (0) |
| Renal cell carcinoma, sarcomatoid | 195 (0.1) |
| Serous carcinoma, NOS | 75 (0) |
| Signet ring cell carcinoma | 460 (0.3) |
| Small cell carcinoma, intermediate cell | 37 (0) |
| Small cell carcinoma, NOS | 25974 (14.4) |
| Soft tissue sarcomas, NOS | 262 (0.1) |
| Solid carcinoma, NOS | 156 (0.1) |
| Specialized gonadal neoplasms | 2 (0) |
| Spindle cell carcinoma, NOS | 100 (0.1) |
| Spindle cell melanoma, NOS | 58 (0) |
| Spindle cell sarcoma | 50 (0) |
| Squamous cell carcinoma, keratinizing, NOS | 543 (0.3) |
| Squamous cell carcinoma, large cell, nonkeratinizing, NOS | 287 (0.2) |
| Squamous cell carcinoma, NOS | 14161 (7.9) |
| Squamous cell carcinoma, spindle cell | 41 (0) |
| Squamous cell neoplasms, other | 37 (0) |
| Struma ovarii, malignant | 603 (0.3) |
| Synovial sarcomas | 25 (0) |
| Thymic epithelial neoplasms | 1 (0) |
| Transitional cell carcinomas, other | 482 (0.3) |
| Trophoblastic neoplasms, other | 6 (0) |
| **Grade (155,759)** |  |
| Well differentiated; differentiated, NOS | 1,996 (1.3) |
| Moderately differentiated; moderately well differentiated; intermediate differentiation | 12,145 (7.8) |
| Poorly differentiated | 35,445 (23) |
| Undifferentiated; anaplastic | 4,899 (3.1) |
| T cell; T-precursor | 29 (0) |
| B cell; pre-B; B-precursor | 438 (0.3) |
| NK (natural killer) cell | 2 (0) |
| Cell type not determined | 100,795 (65) |
| **Diagnostic Confirmation (180,150)** |  |
| Positive Histology | 149,469 (83) |
| Positive Cytology | 20,589 (12) |
| Positive Histology PLUS positive immunophenotyping and/or positive genetic studies | 205 (0.1) |
| Positive microscopic confirmation; method not specified | 101 (0.1) |
| Positive laboratory test/marker study | 86 (0) |
| Direct visualization without microscopic confirmation | 68 (0) |
| Radiography and other imaging techniques without microscopic confirmation | 8,187 (4.5) |
| Clinical diagnosis only | 734 (0.4) |
| Unknown whether microscopically confirmed | 711 (0.4) |
| **Tumor Size in mm (179,977)** | 300.82 ± 419.06 |
| **Regional Nodes Examined (180,150)** | NA |
| **Regional Nodes Positive (180,150)** | NA |
| **Diagnostic and Staging Procedure (180,150)** |  |
| No surgical diagnostic or staging procedure was performed. | 50,040 (28) |
| A biopsy (incisional, needle, or aspiration) was done to a site other than the primary. No exploratory procedure was done. | 43,059 (24) |
| A biopsy (incisional, needle, or aspiration) was done to the primary site. | 84,808 (47) |
| A surgical exploration only. The patient was not biopsied or treated. | 91 (0.1) |
| A surgical procedure with a bypass was performed, but no biopsy was done | 81 (0) |
| An exploratory procedure was performed, and a biopsy of either the primary site or another site was done. | 1,561 (0.9) |
| A bypass procedure was performed, and a biopsy of either the primary site or another site was done. | 107 (0.1) |
| A procedure was done, but the type of procedure is unknown. | 280 (0.2) |
| No information of whether a diagnostic or staging procedure was performed | 123 (0.1) |
| **TNM Staging (T) (180,150)** |  |
| Not applicable | 2,365 (1.3) |
| cT0 | 3,451 (1.9) |
| cT1 | 4,331 (2.4) |
| cT1a | 7,180 (4) |
| cT1b | 9,918 (5.5) |
| cT1b1 | 5 (0) |
| cT1b2 | 12 (0) |
| cT1c | 2,088 (1.2) |
| cT1c3 | 1 (0) |
| cT1mi | 6 (0) |
| CT1Mic | 1 (0) |
| cT2 | 12,462 (6.9) |
| cT2a | 17,932 (10) |
| cT2a1 | 4 (0) |
| cT2a2 | 11 (0) |
| cT2b | 11,325 (6.3) |
| cT2c | 39 (0) |
| cT3 | 26,962 (15) |
| cT3a | 723 (0.4) |
| cT3b | 383 (0.2) |
| cT3c | 72 (0) |
| cT4 | 39,822 (22.1) |
| cT4a | 389 (0.2) |
| cT4b | 1,414 (0.8) |
| cT4c | 148 (0.1) |
| cT4d | 419 (0.2) |
| cTis | 6 (0) |
| cTX | 31,845 (17.7) |
| pTa | 3 (0) |
| pTis | 8 (0) |
| Blank | 6,825 (3.8) |
| **TNM Staging (N) (180,150)** |  |
| Not applicable | 2,376 (1.3) |
| cN0 | 40,258 (22.3) |
| cN1 | 20,206 (11.2) |
| cN1a | 66 (0) |
| cN1b | 145 (0.1) |
| cN1c | 14 (0) |
| cN1mi | 1 (0) |
| cN2 | 61,819 (34.3) |
| cN2a | 312 (0.2) |
| cN2b | 176 (0.1) |
| cN2c | 57 (0) |
| cN3 | 28,467 (15.8) |
| cN3a | 85 (0) |
| cN3b | 134 (0.1) |
| cN3c | 416 (0.2) |
| cNx | 19,864 (11) |
| Blank | 5,754 (3.2) |
| **TNM Staging (M) (180,150)** |  |
| Not applicable | 2,365 (1.3) |
| cM0 | 1,433 (0.8) |
| cM0(i+) | 1 (0) |
| cM1 | 46,508 (25.8) |
| cM1a | 2,688 (1.5) |
| cM1b | 91,475 (50.8) |
| cM1c | 11,276 (6.3) |
| cM1d | 372 (0.2) |
| pM1 | 2,951 (1.6) |
| pM1a | 413 (0.2) |
| pM1b | 11,644 (6.5) |
| pM1c | 4,698 (2.6) |
| pM1d | 319 (0.2) |
| Blank | 4,007 (2.2) |
| **TNM Clinical Staging Group (180,150)** |  |
| 0 | 143 (0.1) |
| 1 | 92 (0.1) |
| 2 | 44 (0) |
| 3 | 99 (0.1) |
| 4 | 152,438 (84.6) |
| Not applicable | 1,881 (1) |
| Unknown | 2,401 (1.3) |
| 1A | 109 (0.1) |
| 1A1 | 5 (0) |
| 1A2 | 4 (0) |
| 1A3 | 7 (0) |
| 1B | 124 (0.1) |
| 1E | 6 (0) |
| 2A | 130 (0.1) |
| 2B | 81 (0) |
| 2C | 10 (0) |
| 2E | 1 (0) |
| 3A | 267 (0.1) |
| 3B | 184 (0.1) |
| 3C | 30 (0) |
| 3C1 | 3 (0) |
| 4A | 5,973 (3.3) |
| 4B | 14,588 (8.1) |
| 4C | 146 (0.1) |
| OC | 11 (0) |
| Blank | 1,373 (0.8) |
| **Clinical Pathology (T) (180,150)** |  |
| Not applicable | 2,294 (1.3) |
| pT0 | 638 (0.4) |
| pT1 | 374 (0.2) |
| pT1a | 532 (0.3) |
| pT1a1 | 1 (0) |
| pT1b | 678 (0.4) |
| pT1b1 | 3 (0) |
| pT1b2 | 1 (0) |
| pT1c | 229 (0.1) |
| pT2 | 997 (0.6) |
| pT2a | 1,165 (0.6) |
| pT2a1 | 2 (0) |
| pT2a2 | 2 (0) |
| pT2b | 629 (0.3) |
| pT2c | 10 (0) |
| pT3 | 1,684 (0.9) |
| pT3a | 708 (0.4) |
| pT3b | 166 (0.1) |
| pT3c | 37 (0) |
| pT4 | 1,696 (0.9) |
| pT4a | 255 (0.1) |
| pT4b | 553 (0.3) |
| pT4c | 19 (0) |
| pT4d | 38 (0) |
| pTa | 1 (0) |
| pTis | 12 (0) |
| pTX | 62,377 (34.6) |
| Blank | 105,049 (58.3) |
| **Clinical Pathology (N) (180,150)** |  |
| Not applicable | 2,303 (1.3) |
| cN0 | 357 (0.2) |
| pN0 | 4,216 (2.3) |
| pN0I- | 15 (0) |
| pN0I+ | 6 (0) |
| pN1 | 1,871 (1) |
| pN1a | 241 (0.1) |
| pN1b | 160 (0.1) |
| pN1c | 18 (0) |
| pN1mi | 10 (0) |
| pN2 | 3,102 (1.7) |
| pN2a | 203 (0.1) |
| pN2b | 212 (0.1) |
| pN2c | 19 (0) |
| pN3 | 1,664 (0.9) |
| pN3a | 99 (0.1) |
| pN3b | 15 (0) |
| pN3c | 35 (0) |
| pNX | 60,868 (33.8) |
| Blank | 104,736 (58.1) |
| **Clinical Pathology (M) (180,150)** |  |
| Not applicable | 2,233 (1.2) |
| cM0 | 575 (0.3) |
| cM1 | 2,329 (1.3) |
| cM1a | 185 (0.1) |
| cM1b | 4,167 (2.3) |
| cM1c | 1,310 (0.7) |
| cM1d | 80 (0) |
| pM0 | 1 (0) |
| pM1 | 12,777 (7.1) |
| pM1a | 1,523 (0.8) |
| pM1b | 22,977 (12.8) |
| pM1c | 4,949 (2.7) |
| pM1d | 395 (0.2) |
| pMX | 1 (0) |
| Blank | 126,648 (70.3) |
| **TNM Pathology Staging Group (180,150)** |  |
| 0 | 135 (0.1) |
| 1 | 50 (0) |
| 2 | 30 (0) |
| 3 | 119 (0.1) |
| 4 | 49,227 (27.3) |
| 88 | 1,866 (1) |
| 99 | 95,580 (53.1) |
| 0A | 1 (0) |
| 1A | 82 (0) |
| 1A1 | 3 (0) |
| 1A2 | 1 (0) |
| 1B | 112 (0.1) |
| 1C | 2 (0) |
| 1E | 3 (0) |
| 1S | 1 (0) |
| 2A | 112 (0.1) |
| 2B | 82 (0) |
| 2C | 14 (0) |
| 3A | 190 (0.1) |
| 3B | 139 (0.1) |
| 3C | 329 (0.2) |
| 3C1 | 1 (0) |
| 3C2 | 4 (0) |
| 3D | 1 (0) |
| 4A | 2,216 (1.2) |
| 4B | 5,358 (3) |
| 4C | 52 (0) |
| OC | 131 (0.1) |
| Blank | 24,309 (13.5) |
| **Analytic Staging Group (180,150)** |  |
| Stage 0 | 223 (0.1) |
| Stage I | 412 (0.2) |
| Stage II | 330 (0.2) |
| Stage III | 1,343 (0.7) |
| Stage IV | 174,506 (97) |
| Occult (lung only) | 6 (0) |
| AJCC staging NA | 1,881 (1) |
| AJCC stage group unknown | 1,449 (0.8) |
| **Metastasis from Bone (180,150)** |  |
| No | 118,645 (66) |
| Not Applicable | 47 (0) |
| Unknown | 2,350 (1.3) |
| Yes | 59,180 (33) |
| **Metastasis from Liver (180,150)** |  |
| No | 138,122 (77) |
| Not Applicable | 50 (0) |
| Unknown | 3,197 (1.8) |
| Yes | 38,781 (22) |
| **Metastasis from Lung (180,150)** |  |
| No | 129,068 (72) |
| Not Applicable | 468 (0.3) |
| Unknown | 4,315 (2.4) |
| Yes | 46,298 (28) |
| **Lymph or Vascular Invasion (180,150)** |  |
| Lymph-vascular invasion is not present (absent) or not identified | 15,106 (8.4) |
| Lymph-vascular invasion is present or identified | 5,502 (2.8) |
| Not applicable | 839 (0.5) |
| Unknown if lymph-vascular invasion is present, or indeterminant | 159,153 (88) |
| **Summary of the treatment status (180,150)** |  |
| Active Surveillance | 229 (0.01) |
| No Treatment Given | 23,919 (13) |
| Treatment Given | 153,242 (85) |
| Unknown | 2,759 (1.5) |
| **Treatment started, days from diagnosis (180,150)** | 19.65 ± 28.24 |
| **First surgical procedure, days from diagnosis (180,150)** | 16.51 ± 42.15 |
| **Definitive surgical procedure, days from diagnosis (180,150)** | 47.07 ± 72.2 |
| **Surgical procedure for primary site (180,150)** |  |
| No surgery | 170,771 (95) |
| Surgery, non-specific | 469 (0.03) |
| Special site-specific surgery | 51 (0) |
| Tumor destruction | 371 (0.2) |
| Tumor resection | 8,199 (4.6) |
| Unknown | 289 (0.2) |
| **Type of surgery at the facillity for primary site (180,150)** |  |
| Minimally invasive | 1,783 (1) |
| Minimally invasive converted to open | 148 (0.1) |
| No surgery | 173,262 (96) |
| Open or unspecified | 4,440 (2.5) |
| Robotic assisted | 432 (0.2) |
| Robotic converted to open | 28 (0) |
| Unknown | 57 (0) |
| **Summary of surgical margins (180,150)** |  |
| Macroscopic residual tumor | 191 (0.1) |
| Margins not evaluable | 733 (0.4) |
| Microscopic residual tumor | 598 (0.3) |
| No primary site surgery | 170,822 (95) |
| No residual tumor | 5,580 (3.1) |
| Residual tumor, nonspecific | 911 (0.5) |
| Unknown | 1,315 (0.7) |
| **Scope of regional lymph node surgery (180,150)** | NA |
| **Scope of regional lymph node surgery in 2012 (146,543)** | NA |
| **Surgery on other sites (180,150)** |  |
| Combination surgery | 119 (0) |
| Non-primary surgery | 1,913 (1) |
| Non-primary surgery, distant lymph nodes | 495 (0.3) |
| Non-primary surgery, distant site | 24,394 (14) |
| Non-primary surgery, regional | 672 (0.4) |
| None | 152,307 (85) |
| Unknown | 250 (0.1) |
| **Readmission within 30-day discharge from surgery (180,150)** |  |
| No surgical procedure of the primary site was performed, or the patient was not readmitted to the same hospital within 30 days of discharge | 175,886 (98) |
| A patient was surgically treated and was readmitted to the same hospital within 30 days of being discharged. This readmission was unplanned | 2,370 (1.3) |
| A patient was surgically treated and was then readmitted to the same hospital within 30 days of being discharged. This readmission was planned | 710 (0.4) |
| A patient was surgically treated and, within 30 days of being discharged, the patient had both a planned and an unplanned readmission to the same hospital | 127 (0.1) |
| It is unknown whether surgery of the primary site was recommended or performed. It is unknown whether the patient was readmitted to the same hospital within 30 days of discharge | 1,057 (0.6) |
| **Reason for no surgery (180,150)** |  |
| Surgery of the primary site was performed | 9,039 (5) |
| Not part of the planned first course treatment | 162,407 (90) |
| Contraindicated due to patient risk factors | 5,752 (3.2) |
| Patient died prior to planned or recommended surgery | 427 (0.2) |
| No reason for not performing recommended surgery was noted in patient record | 415 (0.2) |
| Treatment was refused by the patient, the patient’s family member, or the patient’s guardian | 1,044 (0.6) |
| Unknown if performed | 184 (0.1) |
| Unknown if surgery was recommended or performed | 882 (0.5) |
| **Radiation, days from diagnosis (180,150)** | 35.2 ± 45.32 |
| **Radiation surgery sequence (180,150)** |  |
| No radiation therapy and/or surgical procedures | 151,096 (84) |
| Radiation therapy before surgery | 1,892 (1.1) |
| Radiation therapy after surgery | 22,450 (12.5) |
| Radiation therapy both before and after surgery | 347 (0.2) |
| Intraoperative radiation therapy | 56 (0) |
| Intraoperative radiation therapy with other therapy administered before or after surgery | 15 (0) |
| Sequence unknown | 4,294 (2.4) |
| **Phase I radiation therapy** |  |
| Volume (179,928) | 16.72 ± 22.91 |
| Lymph nodes (179,197) |  |
| Modality (179,926) | 2.76 ± 12.12 |
| Beam tech (179,925) | 3.73 ± 12.6 |
| Dose fraction (179,198) | 61,873.14 ± 48,502.79 |
| Number fraction (179,278) | 49.91 ± 202.33 |
| Total dose (178,924) | 67,098.6 ± 243,876.76 |
| **Phase II radiation therapy** |  |
| Volume (94,557) | 4.99 ± 17.39 |
| Lymph nodes (74,561) | 7.57 ± 26.22 |
| Modality (175,120) | 5.67 ± 22.74 |
| Beam tech (175,120) | 5.8 ± 22.77 |
| Dose fraction (74,898) | 9,822.55 ± 29,677.51 |
| Number fraction (74,846) | 78.47 ± 267.54 |
| Total dose (169,525) | 86,857.37 ± 280,543.75 |
| **Phase III radiation therapy** |  |
| Volume (42,972) | 3.93 ± 17.66 |
| Lymph nodes (31,760) | 1.19 ± 10.66 |
| Modality (31,780) | 0.95 ± 8.94 |
| Beam tech (31,764) | 1.11 ± 8.95 |
| Dose fraction (31,903) | 2,972.24 ± 16,871.61 |
| Number fraction (31,904) | 10.4 ± 99.11 |
| Total dose (31,905) | 9,134.54 ± 94,160.65 |
| **Number of Phases of Radiation Treatment to this Volume (47,709)** | - |
| **Radiation Treatment Discontinued early (39,976)** | - |
| **Total dose of radiation (54,445)** | 48,649.9 ± 209,847.7 |
| **Reason for no radiation (180,150)** |  |
| Administered | 125,382 (70) |
| Contraindicated | 1,930 (1.1) |
| Not administered | 5,648 (3.1) |
| Not administered, patient died | 700 (0.4) |
| Not part of first course | 40,718 (23) |
| Unknown | 5,772 (3.2) |
| **Systemic therapy, days from diagnosis (180,150)** | 44.08 ± 36.35 |
| **Chemotherapy started, days from diagnosis (180,150)** | 44.41 ± 36.74 |
| **Summary of chemotherapy (180,150)** |  |
| Administered | 92,504 (51) |
| Contraindicated | 7,953 (4.4) |
| Not administered | 10,896 (6) |
| Not administered, patient died | 5,920 (3.3) |
| Not part of first course | 58,205 (32) |
| Unknown | 4,672 (2.6) |
| **Hormone therapy started, days from diagnosis (180,150)** | 41.66 ± 64.93 |
| **Summary of hormone therapy (180,150)** |  |
| Administered | 5,548 (3.1) |
| Contraindicated | 1,504 (0.8) |
| Not administered | 4,921 (2.7) |
| Not administered, patient died | 197 (0.1) |
| Not part of first course | 165,729 (92) |
| Unknown | 2,251 (1.2) |
| **Immunotherapy started, days from diagnosis (180,150)** | 64.96 ± 60.23 |
| **Summary of Immunotherapy (180,150)** |  |
| Administered | 18,794 (10) |
| Contraindicated | 539 (0.3) |
| Not administered | 563 (0.3) |
| Not administered, patient died | 552 (0.3) |
| Not part of first course | 159,080 (88) |
| Unknown | 622 (0.3) |
| **Sequencing of systemic treatment and surgery (180,150)** |  |
| No systemic therapy was given; and/or no surgical procedure of primary site | 157,399 (87) |
| Systemic therapy was given before surgical procedure | 1,299 (0.7) |
| Systemic therapy was given after surgical procedure of primary site | 18,273 (10) |
| At least two courses of systemic therapy were given before and at least two more after a surgical procedure of primary site | 492 (0.3) |
| Intraoperative systemic therapy was given | 31 (0) |
| Intraoperative systemic therapy was given during surgical procedure of primary site with other systemic therapy administered before or after surgical procedure | 16 (0) |
| Both surgery and systemic therapy were provided, but the sequence is unknown | 2,640 (1.5) |
| **Other treatment, days from diagnosis (180,150)** | 47.03 ± 65.6 |
| **Summary of other treatment (180,150)** |  |
| None | 178.818 (99) |
| Nonspecific | 990 (0.5) |
| Experimental | 231 (0.1) |
| Clinical trial | 34 (0) |
| Unproven | 42 (0) |
| Refusal of treatment | 31 (0) |
| Reccomended but unknown is administered | 3 (0) |
| Unknown | 1 (0) |
| **Palliative care (180,150)** |  |
| No palliative care provided. Diagnosed at autopsy. | 123,061 (68) |
| Surgery (which may involve a bypass procedure) to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made. | 1,067 (0.6) |
| Radiation therapy to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made. | 29,880 (17) |
| Chemotherapy, hormone therapy, or other systemic drugs to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made. | 10,468 (5.8) |
| Patient received or was referred for pain management therapy with no other palliative care. | 2,586 (1.4) |
| Any combination of above except pain management | 6,390 (3.5) |
| Any combination of above with pain management | 4,195 (2.3) |
| Palliative care was performed or referred, but no information on the type of procedure is available | 2,468 (1.4) |
| Unknown | 35 (0) |
| **30-day mortality (16,999)** |  |
| Patient alive, or died more than 30 days after surgery performed | 7,187 (42) |
| Patient died 30 or fewer days after surgery performed | 422 (2.5) |
| Patient alive with fewer than 30 days of follow-up, surgery date missing, or last contact date missing | 9,390 (55) |
| **90-day mortality (16,999)** |  |
| Patient alive, or died more than 90 days after surgery performed | 6,122 (36) |
| Patient died 90 or fewer days after surgery performed | 1452 (8.5) |
| Patient alive with fewer than 90 days of follow-up, surgery date missing, or last contact date missing | 9,425 (55) |
| **Last contact or death, months from diagnosis (155,733)** | 11.09 ± 15.45 |
| **Vital status at the day of last contact or death (155,733)** | (0,1) |

\*Values represent number of patients and percentages (%) for categorical and mean (SD) for numeric variables.

|  |  |  |  |
| --- | --- | --- | --- |
| **Exact Kaplan-Meier Survival Estimates for ICD-O Topography, Morphology, and Detailed Anatomic Site in the National Cancer Database** | | | |
| **Variable** | **N** | **Deaths** | **Median Survival in months (95% CI)** |
| **Topography** |  |  |  |
| Testis | 472 | 268 | 17.94 (15.18, 26.91) |
| Anus | 51 | 41 | 6.28 (5.6, 13.21) |
| Biliary | 187 | 175 | 2.99 (2.2, 3.71) |
| Bone/joint | 79 | 63 | 7.16 (5.19, 11.33) |
| Breast | 6195 | 4913 | 10.71 (10.22, 11.5) |
| Cervix | 283 | 252 | 3.84 (2.99, 4.76) |
| Colon | 2474 | 2210 | 4.8 (4.4, 5.29) |
| Digestive, other | 337 | 289 | 2.53 (2.2, 2.96) |
| Esophagus | 1745 | 1601 | 4.3 (4, 4.7) |
| Female genitals/placenta | 81 | 53 | 6.01 (2.1, 17.58) |
| Gallbladder | 77 | 68 | 3.335 (2.3, 4.5) |
| Kidney | 4402 | 3742 | 5.88 (5.59, 6.24) |
| Liver | 433 | 390 | 2.56 (2.1, 3.06) |
| Lung, non-small cell | 95423 | 83037 | 5.5 (5.45, 5.59) |
| Lung, other | 9774 | 8969 | 1.8 (1.74, 1.84) |
| Lung, small cell | 22571 | 20687 | 6.24 (6.14, 6.37) |
| Melanoma | 5845 | 4683 | 6.24 (5.98, 6.57) |
| Nasal | 133 | 103 | 7.49 (6.44, 11.83) |
| NHL, extranodal | 127 | 63 | 41 (14.39, \*) |
| NHL, nodal | 349 | 191 | 13.6 (10.61, 20.3) |
| Ovary | 227 | 194 | 4.73 (3.65, 7.4) |
| Pancreas | 1032 | 957 | 2.33 (2.2, 2.6) |
| Prostate | 581 | 419 | 15.84 (12.71, 18.27) |
| Skin, other | 52 | 44 | 4.98 (2.63, 11.5) |
| Small Intestine | 124 | 107 | 4.37 (3.38, 8.64) |
| Soft Tissues | 466 | 420 | 4.83 (4.14, 5.55) |
| Stomach | 873 | 793 | 3.71 (3.25, 4.27) |
| Trachea/Larynx/Mediastinum | 115 | 102 | 7.03 (4.96, 9.2) |
| Urinary tracts | 84 | 78 | 2.37 (1.87, 3.3) |
| Urinary Bladder | 420 | 382 | 3.7 (3.38, 4.34) |
| Uterus | 721 | 622 | 3.84 (3.38, 4.4) |
| **Morphology** |  |  |  |
| Acinar cell carcinoma | 482 | 348 | 16.3 (12.58, 18.63) |
| Acinar cell cystadenocarcinoma | 1 | 1 | 12.88 (\*,\*) |
| Adenocarcinomas, other | 67,551 | 57,694 | 6.37 (6.28, 6.47) |
| Adenosquamous carcinoma | 1,316 | 1,182 | 4.57 (4.14, 4.93) |
| Adnexal and skin appendage neoplasms | 25 | 21 | 3.91 (2.14, 23.23) |
| Atypical carcinoid tumor | 90 | 73 | 5.49 (4.73, 12.85) |
| Basal cell carcinomas, other | 1 | 1 | 0.82 (\*,\*) |
| Basaloid squamous cell carcinoma | 91 | 80 | 5.42 (4.01, 7.95) |
| Blood vessel tumors, other | 12 | 9 | 8.64 (3.35, \*) |
| Carcinoid tumor, NOS | 140 | 110 | 11.43 (8.64, 15.44) |
| Carcinoma, other | 6822 | 6122 | 2.4 (2.3, 2.53) |
| Carcinoma, undifferentiated, NOS | 89 | 77 | 2.96 (2, 4.6) |
| Carcinosarcoma, NOS | 101 | 93 | 2.86 (2.27, 4.01) |
| Cholangiocarcinoma | 139 | 131 | 3.19 (2.3, 3.84) |
| Choriocarcinoma, NOS | 36 | 13 | (16.3, \*) |
| Clear cell adenocarcinoma, NOS | 1800 | 1460 | 8.64 (7.79, 9.4) |
| CNS embryonal tumor, NOS | 2 | 2 | 2.51 (1.31, \*) |
| Combined small cell carcinoma | 385 | 344 | 5.39 (4.7, 7) |
| Complex epithelial neoplasms | 42 | 35 | 6.735 (4.7, 11.3) |
| Complex mixed and stromal neoplasms | 53 | 52 | 3.94 (2.5, 6.7) |
| Cystic, mucinous, and serous carcinomas | 36 | 29 | 11.6 (6.47, 23.43) |
| Ductal and lobular carcinomas, other | 53 | 43 | 10.28 (4.6, 17.87) |
| Endometrioid adenocarcinoma, NOS | 235 | 202 | 4.34 (3.38, 5.59) |
| Ewing sarcoma | 34 | 27 | 11.33 (9.72, 22.67) |
| Fibroepithelial neoplasms | 5 | 4 | 3.88 (3.25, \*) |
| Fibromatous neoplasms | 32 | 29 | 4.67 (2.89, 6.83) |
| Germ cell neoplasms | 9 | 8 | 2.07 (1.38, \*) |
| Giant cell tumors | 2 | 2 | 3.45 (3.29, \*) |
| Granular cell tumors and alveolar soft part sarcomas | 20 | 12 | 35.88 (24.41, \*) |
| Hemangiosarcoma | 93 | 86 | 3.42 (2.5, 4.67) |
| Hepatocellular carcinoma, all types | 374 | 337 | 2.69 (2.14, 3.19) |
| Hepatoid adenocarcinoma | 36 | 33 | 4.11 (3.71, 7.85) |
| Infiltrating duct and lobular carcinoma | 167 | 129 | 18.4 (13.17, 25.36) |
| Infiltrating duct carcinoma, NOS | 3921 | 3118 | 11.53 (10.68, 12.19) |
| Infiltrating duct mixed with other types of carcinoma | 83 | 69 | 12.22 (8, 20.9) |
| Inflammatory carcinoma | 112 | 81 | 14.65 (9.66, 18.69) |
| Large cell carcinoma, NOS | 1020 | 946 | 4.07 (3.71, 4.44) |
| Large cell neuroendocrine carcinoma | 1550 | 1368 | 5.55 (5.09, 6.18) |
| Leiomyosarcoma, NOS | 95 | 83 | 6.8 (4.01, 11.01) |
| Lepidic adenocarcinoma | 221 | 197 | 7.82 (5.88, 10.22) |
| Leukemias, other | 15 | 6 | 9.6 (\*,\*) |
| Lipomatous sarcomas | 21 | 19 | 5.39 (2.76, 17.45) |
| Lobular carcinoma, NOS | 378 | 307 | 12.81 (10.09, 16.36) |
| Lymphoid leukemias | 6 | 4 | 9.265 (3.02, \*) |
| Malignant lymphoma, diffuse | 15 | 10 | 8.275 (4.44, \*) |
| Malignant lymphoma, large B-cell, diffuse, NOS | 287 | 159 | 13.6 (9.72, 20.37) |
| Malignant lymphoma, non-Hodgkin, NOS | 42 | 21 | 16.23 (9, \*) |
| Malignant melanoma, NOS | 5381 | 4317 | 6.1 (5.82, 6.4) |
| Malignant peripheral nerve sheath tumor | 18 | 18 | 4.945 (3.09, 11.4) |
| Malignant tumor, NOS | 25 | 21 | 6.01 (3.48, 12.32) |
| Mature B-cell lymphomas, other | 83 | 32 | 83.94 (28.98, \*) |
| Mature T- and NK-cell lymphomas | 25 | 20 | 6.9 (2.96, 17.81) |
| Melanoma, other | 204 | 157 | 8.71 (7.26, 12.29) |
| Miscellaneous tumors, other | 2 | 2 | 15.065 (4.7, \*) |
| Mixed cell adenocarcinoma | 67 | 51 | 6.31 (4.86, 13.17) |
| Mucin-producing adenocarcinoma | 231 | 196 | 5.65 (4.6, 8.41) |
| Mucinous adenocarcinoma | 933 | 802 | 6.01 (5.16, 6.8) |
| Mucoepidermoid carcinoma | 14 | 14 | 3.6 (1.35, 39.85) |
| Mullerian mixed tumor | 31 | 30 | 4.8 (1.91, 7.56) |
| Myomatous neoplasms, other | 36 | 31 | 5.49 (3.81, 7.82) |
| Myxomatous neoplasms | 2 | 1 | 11.14 (\*,\*) |
| Neoplasm, malignant | 4745 | 4376 | 1.31 (1.25, 1.38) |
| Neuroendocrine carcinoma, NOS | 2657 | 2400 | 5.6 (5.26, 5.98) |
| Neuroepitheliomatous neoplasms | 11 | 6 | 44.65 (27.4, \*) |
| Nodular melanoma | 309 | 251 | 7.82 (7.13, 9.07) |
| Non-small cell carcinoma | 11807 | 10716 | 3.98 (3.88, 4.11) |
| Oat cell carcinoma | 98 | 94 | 6.64 (4.5, 8.48) |
| Osseous and chondromatous neoplasms | 43 | 37 | 6.83 (4.67, 10.18) |
| Papillary adenocarcinoma, NOS | 666 | 541 | 11.43 (9.92, 13.67) |
| Papillary carcinoma, NOS | 62 | 52 | 6.11 (3.32, 11.73) |
| Papillary transitional cell carcinoma | 90 | 88 | 5.225 (3.65, 6.83) |
| Paragangliomas and glomus tumors | 2 | 1 | 30.52 (\*,\*) |
| Plasma cell tumors | 3 | 2 | 12 (7.29, \*) |
| Pleomorphic carcinoma | 120 | 100 | 3.5 (2.96, 5.19) |
| Pseudosarcomatous carcinoma | 458 | 423 | 3.06 (2.76, 3.42) |
| Renal cell carcinoma, NOS | 1939 | 1691 | 4.93 (4.57, 5.32) |
| Renal cell carcinoma, other | 21 | 16 | 7.2 (3.09, 12.25) |
| Renal cell carcinoma, sarcomatoid | 171 | 156 | 4.01 (3.42, 4.93) |
| Serous carcinoma, NOS | 66 | 50 | 6.095 (4.17, 15.93) |
| Signet ring cell carcinoma | 438 | 392 | 3.94 (3.42, 4.9) |
| Small cell carcinoma, intermediate cell | 34 | 31 | 4.17 (2.07, 11.93) |
| Small cell carcinoma, NOS | 22231 | 20375 | 6.28 (6.14, 6.4) |
| Soft tissue sarcomas, NOS | 238 | 221 | 3.81 (3.25, 5.03) |
| Solid carcinoma, NOS | 115 | 81 | 12.88 (10.22, 22.54) |
| Specialized gonadal neoplasms | 2 | 2 | 11.55 (1.05, \*) |
| Spindle cell carcinoma, NOS | 79 | 75 | 2.46 (2.1, 3.61) |
| Spindle cell melanoma, NOS | 54 | 40 | 6.08 (4.34, 11.2) |
| Spindle cell sarcoma | 42 | 35 | 3.45 (2.43, 4.44) |
| Squamous cell carcinoma, keratinizing, NOS | 469 | 432 | 3.78 (3.25, 4.7) |
| Squamous cell carcinoma, large cell, nonkeratinizing, NOS | 253 | 234 | 4.11 (3.5, 4.86) |
| Squamous cell carcinoma, NOS | 12370 | 11341 | 3.81 (3.71, 3.91) |
| Squamous cell carcinoma, spindle cell | 39 | 36 | 2.89 (2.3, 4.86) |
| Squamous cell neoplasms, other | 37 | 33 | 3.91 (1.84, 6.8) |
| Struma ovarii, malignant | 533 | 320 | 15.18 (13.73, 19.35) |
| Synovial sarcomas | 18 | 18 | 3.67 (2.56, 12.91) |
| Thymic epithelial neoplasms | 1 | 1 | 1.22 (\*,\*) |
| Transitional cell carcinomas, other | 414 | 376 | 3.52 (3.12, 4.07) |
| Trophoblastic neoplasms, other | 6 | 4 | 24.33 (3.42, \*) |
| **Most Common Anatomic Sites** |  |  |  |
| Appendix | 11 | 10 | 12 (3.81, \*) |
| Breast, axillary tail | 53 | 43 | 8.84 (5.95, 25.63) |
| Breast, central | 238 | 181 | 12.16 (9.56, 17.12) |
| Breast, lower inner quadrant | 157 | 131 | 8.77 (7.03, 13.6) |
| Breast, lower outer quadrant | 276 | 215 | 9.76 (7.79, 15.51) |
| Breast, nipple | 27 | 19 | 14.93 (6.41, \*) |
| Breast, NOS | 2746 | 2196 | 9.53 (8.44, 10.28) |
| Breast, overlapping | 1140 | 924 | 11.24 (9.72, 12.58) |
| Breast, upper inner quadrant | 303 | 228 | 13.17 (10.38, 17.94) |
| Breast, upper outer quadrant | 1255 | 976 | 13.73 (12.02, 15.74) |
| Bronchus, main | 6226 | 5686 | 4.44 (4.21, 4.67) |
| Cardia, NOS | 481 | 431 | 5.42 (4.67, 6.5) |
| Cecum | 336 | 305 | 4.17 (3.55, 5.13) |
| Colon, ascending | 285 | 260 | 4.3 (3.52, 5.5) |
| Colon, descending | 67 | 59 | 4.8 (2.99, 9.26) |
| Colon, hepatic flexure | 85 | 79 | 3.35 (2.92, 5.75) |
| Colon, NOS | 459 | 404 | 3.06 (2.6, 3.84) |
| Colon, overlapping | 31 | 31 | 2.73 (1.68, 8.54) |
| Colon, sigmoid | 362 | 320 | 6.31 (4.96, 8.57) |
| Colon, splenic flexure | 33 | 31 | 3.84 (2.69, 11.24) |
| Colon, transverse | 86 | 74 | 3.25 (2.53, 5.49) |
| Corpus uteri | 34 | 28 | 3.075 (2.2, 11.33) |
| Corpus uteri, overlapping | 3 | 2 | 1.9 (1.15, \*) |
| Ear, external | 36 | 29 | 6.57 (3.5, 18) |
| Endometrium | 524 | 460 | 3.98 (3.45, 4.7) |
| Esophagus, abdominal | 8 | 7 | 2.775 (1.38, \*) |
| Esophagus, cervical | 4 | 4 | 6.965 (0.43, \*) |
| Esophagus, lower third | 1070 | 989 | 4.57 (4.24, 5.09) |
| Esophagus, middle third | 173 | 159 | 4.3 (3.55, 5.75) |
| Esophagus, NOS | 284 | 251 | 3.48 (2.86, 4.6) |
| Esophagus, overlapping | 118 | 111 | 4.53 (3.78, 5.88) |
| Esophagus, thoracic | 49 | 44 | 3.94 (2.5, 9) |
| Esophagus, upper third | 39 | 36 | 2.46 (1.58, 3.84) |
| Eyelid | 1 | 1 | 4.14 (\*,\*) |
| Fundus uteri | 8 | 7 | 3.71 (2.76, \*) |
| Gastric andrum | 41 | 40 | 2.37 (1.5, 4.63) |
| Intestinal tract, NOS | 7 | 7 | 1.94 (1.15, \*) |
| Isthmus uteri | 3 | 3 | 2.69 (0.9, \*) |
| Kidney, NOS | 4313 | 3662 | 5.91 (5.62, 6.31) |
| Langerhans, islets | 2 | 2 | 10.025 (0.76, \*) |
| Lip, NOS | 5 | 3 | 6.74 (6.6, \*) |
| Lung, lower lobe | 29612 | 26111 | 5.19 (5.09, 5.29) |
| Lung, middle lobe | 4854 | 4307 | 5.65 (5.32, 6) |
| Lung, NOS | 21395 | 18923 | 4.27 (4.17, 4.4) |
| Lung, overlapping | 1783 | 1589 | 4.63 (4.2, 5.13) |
| Lung, upper lobe | 63898 | 56077 | 5.62 (5.55, 5.72) |
| Myometrium | 7 | 7 | 4.4 (3.4, \*) |
| Pancreas, body | 122 | 111 | 2.83 (2.37, 4.2) |
| Pancreas, head | 300 | 277 | 2.53 (2.04, 3.22) |
| Pancreas, NOS | 326 | 311 | 2.14 (1.87, 2.33) |
| Pancreas, other | 14 | 12 | 1.77 (0.99, \*) |
| Pancreas, overlapping | 80 | 70 | 2.5 (1.71, 3.25) |
| Pancreas, tail | 187 | 173 | 2.5 (2.14, 3.12) |
| Pancreatic duct | 1 | 1 | 6.77 (\*,\*) |
| Prostate gland | 581 | 419 | 15.84 (12.71, 18.27) |
| Pylorus | 4 | 4 | 2.105 (0.2, \*) |
| Rectosigmoid junction | 202 | 182 | 6.11 (4.53, 8.8) |
| Rectum, NOS | 510 | 448 | 7.79 (6.74, 9.49) |
| Rel pelvis | 89 | 80 | 4.01 (3.29, 6.11) |
| Skin, face other | 111 | 89 | 7.95 (6.47, 9.4) |
| Skin, lower limb | 188 | 146 | 8.54 (6.8, 11.56) |
| Skin, NOS | 4457 | 3576 | 5.95 (5.65, 6.28) |
| Skin, overlapping | 10 | 9 | 2.305 (0.8, \*) |
| Skin, scalp, and neck | 192 | 140 | 8.48 (6.77, 12.94) |
| Skin, trunk | 588 | 485 | 6.41 (5.75, 7.39) |
| Skin, upper limb | 257 | 205 | 6.9 (5.32, 8.94) |
| Stomach, body | 51 | 49 | 2.69 (1.45, 3.91) |
| Stomach, fundus | 33 | 31 | 2.43 (1.31, 3.38) |
| Stomach, greater curvature NOS | 25 | 21 | 2.83 (1.84, 10.22) |
| Stomach, lesser curvature NOS | 21 | 19 | 6.18 (1.77, 15.34) |
| Stomach, NOS | 176 | 157 | 2.63 (2.3, 3.25) |
| Stomach, overlapping | 41 | 41 | 1.64 (1.15, 2.63) |
| Uterus, NOS | 142 | 115 | 3.6 (2.76, 5.32) |
| **Least Common Anatomic Sites** |  |  |  |
| Adrenal gland, NOD | 1 | 0 | NA |
| Anal canal | 19 | 15 | 9.36 (4.73, \*) |
| Anus, NOS | 14 | 11 | 6.28 (5.22, \*) |
| Autonomic NS, NOS | 6 | 6 | 6.21 (3.84, \*) |
| Bile duct, extrahepatic | 55 | 50 | 2.23 (1.81, 5.36) |
| Bile duct, intrahepatic | 82 | 79 | 3.675 (2.73, 4.9) |
| Biliary, NOS | 36 | 33 | 2.365 (1.31, 4.07) |
| Biliary, overlapping | 4 | 4 | 0.825 (0.26, \*) |
| Bladder, anterior wall | 12 | 12 | 4.945 (2.14, \*) |
| Bladder, dome | 17 | 14 | 5.49 (3.45, 35.09) |
| Bladder, lateral wall | 51 | 45 | 4.24 (3.38, 6.97) |
| Bladder, neck | 8 | 7 | 4.09 (2.96, \*) |
| Bladder, NOS | 246 | 225 | 3.45 (2.83, 4.11) |
| Bladder, overlapping | 49 | 46 | 3.91 (2.86, 6.21) |
| Bladder, posterior wall | 19 | 17 | 3.48 (2.3, 10.41) |
| Bladder, trigone | 14 | 12 | 3.98 (1.97, \*) |
| Bone marrow | 16 | 13 | 4.73 (2.5, \*) |
| Bone, NOS | 11 | 5 | (3.19, \*) |
| Bones, overlapping | 1 | 1 | 14.65 (\*,\*) |
| Bones, pelvis sacrum and coccyx | 16 | 15 | 5.24 (2.73, 15.38) |
| Bones, skull and face | 13 | 10 | 11.2 (3.75, \*) |
| Breast, NOS | 1 | 0 | NA |
| Breast, upper outer quadrant | 1 | 0 | NA |
| Cardia, NOS | 1 | 1 | 0.43 (\*,\*) |
| Cervix uteri | 242 | 218 | 3.84 (2.86, 4.83) |
| Cervix uteri, overlapping | 8 | 7 | 3.38 (1.15, \*) |
| Ciliary body | 2 | 1 | 6.5 (6.5, \*) |
| Cloacogenic zone | 1 | 1 | 5.95 (\*,\*) |
| Colon, transverse | 1 | 0 | NA |
| Conjunctiva | 2 | 0 | NA |
| Digestive, overlapping | 27 | 23 | 1.87 (1.45, 4.8) |
| Duodenum | 47 | 44 | 3.635 (2.4, 7.6) |
| Ear, external | 2 | 2 | 10.595 (1.71, \*) |
| Ear, middle | 6 | 3 | 13.9 (1.81, \*) |
| Endocervix | 33 | 27 | 5.29 (2.7, 11.27) |
| Esophagus, lower third | 1 | 0 | NA |
| Exocervix | 1 | 1 | 1.25 (\*,\*) |
| Eye, NOS | 2 | 0 | NA |
| Eyelid | 1 | 1 | 9.72 (\*,\*) |
| Fallopian tube | 6 | 4 | 22.37 (4.34, \*) |
| Female genitals, NOS | 47 | 40 | 1.66 (1.2, 11.2) |
| Female genitals, other | 2 | 1 | 2.1 (2.1, \*) |
| Female genitals, overlapping | 6 | 6 | 1.66 (0.62, \*) |
| Gallbladder | 78 | 68 | 3.35 (2.3, 4.5) |
| Gastric andrum | 1 | 0 | NA |
| Gastrointestinal, NOS | 310 | 266 | 2.53 (2.23, 3.22) |
| Glottis | 4 | 4 | 10.89 (7.1, \*) |
| Heart | 35 | 34 | 6.37 (3.48, 10.22) |
| Heart mediastinum, overlapping | 1 | 0 | NA |
| Ileum | 15 | 12 | 8.8 (3.45, \*) |
| Jejunum | 14 | 11 | 9.465 (6.54, \*) |
| Kidney, NOS | 3 | 2 | 2 (0.23, \*) |
| Lacrimal gland | 1 | 0 | NA |
| Larynx, NOS | 17 | 17 | 4.73 (2.6, 10.74) |
| Limb bone, NOS | 4 | 2 | 38.14 (3.58, \*) |
| Lip, NOS | 1 | 1 | 6.8 (\*,\*) |
| Liver | 434 | 390 | 2.6 (2.1, 3.06) |
| Long bones and lower limb | 21 | 18 | 8.1 (4.7, 28.06) |
| Long bones and upper limb, scapula | 5 | 4 | 6.83 (6.47, \*) |
| Lung, middle lobe | 1 | 1 | 2.5 (\*,\*) |
| Lung, NOS | 2 | 1 | 2.04 (2.04,\*) |
| Lymph nodes, axilla, and arm | 8 | 3 | (13.6, \*) |
| Lymph nodes, head face and neck | 16 | 7 | 38.6 (8.1, \*) |
| Lymph nodes, inguinal | 3 | 1 | (1.35, \*) |
| Lymph nodes, intraabdominal | 27 | 15 | 9.69 (6.64, \*) |
| Lymph nodes, intrathoracic | 3 | 2 | 2.73 (1.77, \*) |
| Lymph nodes, multiple | 129 | 72 | 11.27 (8.54, \*) |
| Lymph nodes, NOS | 153 | 85 | 14.6 (10.84, 30.49) |
| Lymph nodes, pelvis | 5 | 3 | 9.72 (3.91, \*) |
| Mandible | 2 | 1 | 0.62 (\*,\*) |
| Mediastinum, anterior | 15 | 13 | 8.08 (4.73, 34.27) |
| Mediastinum, NOS | 34 | 29 | 7.605 (4.57, 10.41) |
| Mediastinum, posterior | 3 | 2 | 7.095 (4.93, \*) |
| Nasal cavity | 54 | 38 | 11.07 (7.1, 26.45) |
| Nasopharynx, NOS | 4 | 2 | 11 (1.58, \*) |
| Nasopharynx, overlapping | 1 | 1 | 2.96 (\*,\*) |
| Orbit, NOS | 7 | 4 | 78.32 (49.45, \*) |
| Oropharynx, overlapping | 1 | 0 | NA |
| Ovary | 227 | 194 | 4.73 (3.65, 7.4) |
| Pancreas, head | 1 | 1 | 1.05 (\*,\*) |
| Pelvis, NOS | 1 | 0 | NA |
| Peripheral and autonomic NS, thorax | 3 | 3 | 3.06 (2.3, \*) |
| Peripheral and autonomic NS, trunk NOS | 1 | 1 | 4.76 (\*,\*) |
| Peritoneum, NOS | 1 | 1 | 9 (\*,\*) |
| Placenta | 19 | 1 | NA |
| Pleura, NOS | 1 | 0 | NA |
| Rectosigmoid junction | 1 | 0 | NA |
| Rectum anus and anal canal, overlapping | 17 | 14 | 6.18 (4.37, \*) |
| Rectum, NOS | 1 | 1 | 15.8 (\*,\*) |
| Respiratory and intrathoracic, overlapping | 2 | 1 | 0.62 (0.62, \*) |
| Respiratory, ill defined | 1 | 1 | 64.82 (\*,\*) |
| Retroperitoneum | 3 | 2 | 8.41 (7.62, \*) |
| Rib sternum and clavicle | 4 | 3 | 20.585 (3.32, \*) |
| Sinus, ethmoid | 18 | 14 | 9.315 (4.01, \*) |
| Sinus, frontal | 3 | 1 | (1.25, \*) |
| Sinus, maxillary | 31 | 23 | 7.29 (3.65, 34.33) |
| Sinus, NOS | 15 | 14 | 8.61 (1.94, 20.57) |
| Sinus, overlapping | 3 | 2 | 9.36 (1.45, \*) |
| Sinus, sphenoid | 10 | 9 | 2.875 (1.2, \*) |
| Skin, face other | 9 | 5 | 18.33 (4.67, \*) |
| Skin, lower limb | 4 | 4 | 17.15 (1.81, \*) |
| Skin, NOS | 12 | 9 | 4.155 (2.63, \*) |
| Skin, scalp, and neck | 11 | 10 | 2.14 (1.45, \*) |
| Skin, trunk | 15 | 13 | 7.98 (2.14, 21.68) |
| Skin, upper limb | 5 | 5 | 3.91 (1.68, \*) |
| Small intestine, NOS | 50 | 41 | 3.65 (2.99, 10.22) |
| Soft tissues, abdomen | 29 | 28 | 2.89 (1.51, 15.51) |
| Soft tissues, head face and neck | 50 | 39 | 7.82 (6.01, 12) |
| Soft tissues, lower limb | 94 | 83 | 6.54 (5.36, 13.11) |
| Soft tissues, NOS | 100 | 92 | 3.42 (2.53, 4.53) |
| Soft tissues, overlapping | 2 | 2 | 20.255 (6.7, \*) |

|  |  |  |
| --- | --- | --- |
| **Unadjusted Cox Regression for ICD-O Topography, Morphology, and Detailed Anatomic Site** | | |
| **Variable  (Total Number / No. of Events)** | **Unadjusted HR (95% CI)** | ***p-value*** |
| **Topography (155,733 / 135,916)** |  |  |
| Anus | 1.46 (1.059, 2.012) | *0.021* |
| Biliary | 2.857 (2.395, 3.408) | *<0.001* |
| Bone/joint | 1.341 (1.029, 1.748) | *0.03* |
| Breast | 1.206 (1.091, 1.332) | *<0.001* |
| Cervix | 2.37 (2.028, 2.771) | *<0.001* |
| Colon | 1.878 (1.692, 2.085) | *<0.001* |
| Digestive, other | 2.693 (2.319, 3.129) | *<0.001* |
| Esophagus | 2.229 (2.001, 2.482) | *<0.001* |
| Female genitals/placenta | 1.155 (0.868, 1.537) | *0.323* |
| Gallbladder | 2.559 (1.98, 3.306) | *<0.001* |
| Kidney | 1.627 (1.471, 1.8) | *<0.001* |
| Liver | 3.1 (2.701, 3.559) | *<0.001* |
| Lung, non-small cell | 1.758 (1.597, 1.935) | *<0.001* |
| Lung, other | 3.64 (3.3, 4.014) | *<0.001* |
| Lung, small cell | 2.033 (1.845, 2.239) | *<0.001* |
| Melanoma | 1.465 (1.326, 1.62) | *<0.001* |
| Nasal | 1.345 (1.084, 1.669) | *0.007* |
| NHL, extra-nodal | 0.678 (0.52, 0.883) | *0.004* |
| NHL, nodal | 0.855 (0.72, 1.014) | *0.073* |
| Ovary | 1.679 (1.417, 1.991) | *<0.001* |
| Pancreas | 3.225 (2.875, 3.617) | *0.001* |
| Skin, other | 1.739 (1.275, 2.373) | *<0.001* |
| Small Intestine | 1.818 (1.47, 2.247) | *<0.001* |
| Soft Tissues | 2.002 (1.749, 2.293) | *<0.001* |
| Stomach | 2.255 (2.004, 2.539) | *<0.001* |
| Testis | 0.692 (0.594, 0.807) | *<0.001* |
| Trachea/Larynx/Mediastinum | 1.731 (1.394, 2.15) | *<0.001* |
| Urinary tracts | 3.086 (2.424, 3.93) | *<0.001* |
| Urinary Bladder | 2.481 (2.16, 2.85) | *<0.001* |
| Uterus | 2.057 (1.817, 2.328) | *<0.001* |
| **Morphology (155,733 / 135,916)** |  |  |
| Acinar cell carcinoma | 2.539 (1.46, 4.417) | *<0.001* |
| Acinar cell cystadenocarcinoma | 3.734 (0.489, 28.547) | *0.204* |
| Adenocarcinomas, other | 4.247 (2.466, 7.315) | *<0.001* |
| Adenosquamous carcinoma | 5.296 (3.066, 9.147) | *<0.001* |
| Adnexal and skin appendage neoplasms | 4.101 (2.053, 8.19) | *<0.001* |
| Atypical carcinoid tumor | 3.83 (2.123, 6.91) | *<0.001* |
| Basal cell carcinomas, other | 57.296 (7.5, 437.729) | *<0.001* |
| Basaloid squamous cell carcinoma | 4.807 (2.675, 8.638) | *<0.001* |
| Blood vessel tumors, other | 3.049 (1.303, 7.133) | *0.01* |
| Carcinoid tumor, NOS | 3.166 (1.782, 5.626) | *<0.001* |
| Carcinoma, other | 7.255 (4.21, 12.501) | *<0.001* |
| Carcinoma, undifferentiated, NOS | 6.313 (3.508, 11.363) | *<0.001* |
| Carcinosarcoma, NOS | 7.031 (3.935, 12.562) | *<0.001* |
| Cholangiocarcinoma | 7.553 (4.272, 13.355) | *<0.001* |
| Clear cell adenocarcinoma, NOS | 3.404 (1.972, 5.877) | *<0.001* |
| CNS embryonal tumor, NOS | 14.365 (3.242, 63.66) | *<0.001* |
| Combined small cell carcinoma | 5.185 (2.98, 9.021) | *<0.001* |
| Complex epithelial neoplasms | 4.07 (2.153, 7.692) | *<0.001* |
| Complex mixed and stromal neoplasms | 6.523 (3.552, 11.978) | *<0.001* |
| Cystic, mucinous, and serous carcinomas | 3.128 (1.626, 6.018) | *<0.001* |
| Ductal and lobular carcinomas, other | 3.44 (1.85, 6.398) | *<0.001* |
| Endometrioid adenocarcinoma, NOS | 4.928 (2.813, 8.635) | *<0.001* |
| Ewing sarcoma | 2.98 (1.538, 5.775) | *0.001* |
| Fibroepithelial neoplasms | 7.054 (2.3, 21.635) | *<0.001* |
| Fibromatous neoplasms | 5.747 (2.988, 11.056) | *<0.001* |
| Germ cell neoplasms | 5.851 (2.425, 14.116) | *<0.001* |
| Giant cell tumors | 10.096 (2.278, 44.739) | *0.002* |
| Granular cell tumors and alveolar soft part sarcomas | 1.576 (0.719, 3.453) | *0.256* |
| Hemangiosarcoma | 6.908 (3.855, 12.378) | *<0.001* |
| Hepatocellular carcinoma | 8.209 (4.717, 14.285) | *<0.001* |
| Hepatoid adenocarcinoma | 5.533 (2.912, 10.513) | *<0.001* |
| Infiltrating duct and lobular carcinoma | 2.536 (1.434, 4.486) | *0.001* |
| Infiltrating duct carcinoma, NOS | 3.072 (1.782, 5.297) | *<0.001* |
| Infiltrating duct mixed with other types of carcinoma | 2.954 (1.633, 5.342) | *<0.001* |
| Inflammatory carcinoma | 2.643 (1.472, 4.748) | *0.001* |
| Large cell carcinoma, NOS | 5.996 (3.469, 10.364) | *<0.001* |
| Large cell neuroendocrine carcinoma | 4.987 (2.888, 8.611) | *<0.001* |
| Leiomyosarcoma, NOS | 4.378 (2.44, 7.856) | *<0.001* |
| Lepidic adenocarcinoma | 3.874 (2.21, 6.791) | *<0.001* |
| Leukemias, other | 1.483 (0.564, 3.902) | *0.424* |
| Lipomatous sarcomas | 4.981 (2.46, 10.086) | *<0.001* |
| Lobular carcinoma, NOS | 3.126 (1.794, 5.445) | *<0.001* |
| Lymphoid leukemias | 2.769 (0.903, 8.492) | 0.075 |
| Malignant lymphoma, diffuse | 2.804 (1.229, 6.394) | *0.014* |
| Malignant lymphoma, large B-cell, diffuse, NOS | 2.255 (1.281, 3.97) | *0.005* |
| Malignant lymphoma, non-Hodgkin, NOS | 2.001 (1.002, 3.997) | *0.05* |
| Malignant melanoma, NOS | 3.905 (2.265, 6.73) | *<0.001* |
| Malignant peripheral nerve sheath tumor | 6.265 (3.07, 12.787) | *<0.001* |
| Malignant tumor, NOS | 4.938 (2.473, 9.862) | *<0.001* |
| Mature B-cell lymphomas, other | 1.301 (0.683, 2.478) | *0.424* |
| Mature T- and NK-cell lymphomas | 3.948 (1.964, 7.937) | *<0.001* |
| Melanoma, other | 3.153 (1.791, 5.551) | *<0.001* |
| Miscellaneous tumors, other | 3.8 (0.858, 16.839) | *0.079* |
| Mixed cell adenocarcinoma | 3.505 (1.907, 6.444) | *<0.001* |
| Mucin-producing adenocarcinoma | 4.167 (2.377, 7.305) | *<0.001* |
| Mucinous adenocarcinoma | 4.442 (2.568, 7.685) | *<0.001* |
| Mucoepidermoid carcinoma | 6.122 (2.878, 13.024) | *<0.001* |
| Mullerian mixed tumor | 7.327 (3.822, 14.046) | *<0.001* |
| Myomatous neoplasms, other | 5.197 (2.72, 9.932) | *<0.001* |
| Myxomatous neoplasms | 2.26 (0.296, 17.276) | *0.432* |
| Neoplasm, malignant | 12.453 (7.225, 21.464) | *<0.001* |
| Neuroendocrine carcinoma, NOS | 5.272 (3.057, 9.093) | *<0.001* |
| Neuroepitheliomatous neoplasms | 1.466 (0.557, 3.858) | *0.438* |
| Nodular melanoma | 3.512 (2.011, 6.132) | *<0.001* |
| Non-small cell carcinoma | 5.771 (3.35, 9.942) | *<0.001* |
| Oat cell carcinoma | 5.496 (3.077, 9.815) | *<0.001* |
| Osseous and chondromatous neoplasms | 4.566 (2.427, 8.59) | *<0.001* |
| Papillary adenocarcinoma, NOS | 3.174 (1.831, 5.501) | *<0.001* |
| Papillary carcinoma, NOS | 4.348 (2.368, 7.984) | *<0.001* |
| Papillary transitional cell carcinoma | 6.11 (3.413, 10.939) | *<0.001* |
| Paragangliomas and glomus tumors | 1.181 (0.155, 9.026) | *0.873* |
| Plasma cell tumors | 2.714 (0.612, 12.025) | *0.189* |
| Pleomorphic carcinoma | 5.104 (2.864, 9.097) | *<0.001* |
| Pseudosarcomatous carcinoma | 7.654 (4.407, 13.291) | *<0.001* |
| Renal cell carcinoma, NOS | 4.898 (2.838, 8.453) | *<0.001* |
| Renal cell carcinoma, other | 4.141 (1.992, 8.608) | *<0.001* |
| Renal cell carcinoma, sarcomatoid | 5.705 (3.24, 10.045) | *<0.001* |
| Serous carcinoma, NOS | 3.373 (1.832, 6.209) | *<0.001* |
| Signet ring cell carcinoma | 5.396 (3.105, 9.377) | *<0.001* |
| Small cell carcinoma, intermediate cell | 5.239 (2.741, 10.011) | *<0.001* |
| Small cell carcinoma, NOS | 5.361 (3.112, 9.234) | *<0.001* |
| Soft tissue sarcomas, NOS | 6.354 (3.632, 11.117) | *<0.001* |
| Solid carcinoma, NOS | 2.515 (1.4, 4.517) | *0.002* |
| Specialized gonadal neoplasms | 5.072 (1.145, 22.477) | *0.033* |
| Spindle cell carcinoma, NOS | 9.211 (5.112, 16.598) | *<0.001* |
| Spindle cell melanoma, NOS | 3.595 (1.923, 6.721) | *<0.001* |
| Spindle cell sarcoma | 6.792 (3.594, 12.837) | *<0.001* |
| Squamous cell carcinoma, keratinizing, NOS | 6.479 (3.731, 11.248) | *<0.001* |
| Squamous cell carcinoma, large cell, nonkeratinizing, NOS | 6.202 (3.548, 10.842) | *<0.001* |
| Squamous cell carcinoma, NOS | 6.352 (3.687, 10.943) | *<0.001* |
| Squamous cell carcinoma, spindle cell | 7.789 (4.131, 14.687) | *<0.001* |
| Squamous cell neoplasms, other | 5.54 (2.916, 10.525) | *<0.001* |
| Struma ovarii, malignant | 2.014 (1.157, 3.507) | *0.013* |
| Synovial sarcomas | 6.761 (3.313, 13.799) | *<0.001* |
| Thymic epithelial neoplasms | 33.28 (4.353, 254.414) | *<0.001* |
| Transitional cell carcinomas, other | 6.789 (3.906, 11.802) | *<0.001* |
| Trophoblastic neoplasms, other | 2.376 (0.775, 7.286) | *0.13* |
| **Detailed Anatomic Site (151,636 / 132,633)** |  |  |
| Appendix | 1.358 (0.725, 2.542) | 0.34 |
| Breast, axillary tail | 1.225 (0.895, 1.677) | 0.205 |
| Breast, central | 1.05 (0.882, 1.25) | 0.586 |
| Breast, lower inner quadrant | 1.355 (1.114, 1.649) | 0.002 |
| Breast, lower outer quadrant | 1.177 (0.998, 1.387) | 0.053 |
| Breast, nipple | 0.896 (0.566, 1.419) | 0.64 |
| Breast, NOS | 1.312 (1.181, 1.456) | *<0.001* |
| Breast, overlapping | 1.207 (1.075, 1.354) | 0.001 |
| Breast, upper inner quadrant | 1.037 (0.882, 1.218) | 0.663 |
| Breast, upper outer quadrant | 1.076 (0.96, 1.207) | 0.209 |
| Bronchus, main | 2.199 (1.991, 2.429) | *<0.001* |
| Cardia, NOS | 1.862 (1.628, 2.13) | *<0.001* |
| Cecum | 2.102 (1.813, 2.436) | *<0.001* |
| Colon, ascending | 2.011 (1.723, 2.347) | *<0.001* |
| Colon, descending | 1.881 (1.432, 2.47) | *<0.001* |
| Colon, hepatic flexure | 2.322 (1.826, 2.953) | *<0.001* |
| Colon, NOS | 2.33 (2.033, 2.672) | *<0.001* |
| Colon, overlapping | 2.833 (1.967, 4.081) | *<0.001* |
| Colon, sigmoid | 1.639 (1.417, 1.896) | *<0.001* |
| Colon, splenic flexure | 2.182 (1.515, 3.143) | *<0.001* |
| Colon, transverse | 2.319 (1.811, 2.97) | *<0.001* |
| Corpus uteri | 1.683 (1.148, 2.467) | 0.008 |
| Corpus uteri, overlapping | 5.49 (1.368, 22.025) | 0.017 |
| Ear, external | 1.44 (0.988, 2.098) | 0.578 |
| Endometrium | 2.072 (1.815, 2.366) | *<0.001* |
| Esophagus, abdominal | 2.519 (1.194, 5.317) | 0.015 |
| Esophagus, cervical | 2.001 (0.748, 5.357) | 0.167 |
| Esophagus, lower third | 2.156 (1.923, 2.416) | *<0.001* |
| Esophagus, middle third | 2.221 (1.851, 2.666) | *<0.001* |
| Esophagus, NOS | 2.295 (1.962, 2.683) | *<0.001* |
| Esophagus, overlapping | 2.581 (2.094, 3.182) | *<0.001* |
| Esophagus, thoracic | 2.124 (1.557, 2.897) | *<0.001* |
| Esophagus, upper third | 3.233 (2.3, 4.544) | *<0.001* |
| Eyelid | 3.225 (0.453, 22.948) | 0.242 |
| Fundus uteri | 3.073 (1.456, 6.486) | 0.003 |
| Gastric andrum | 3.758 (2.717, 5.197) | *<0.001* |
| Intestinal tract, NOS | 3.846 (1.822, 8.118) | *<0.001* |
| Isthmus uteri | 5.368 (1.724, 16.712) | 0.004 |
| Kidney, NOS | 1.617 (1.461, 1.789) | *<0.001* |
| Langerhans, islets | 2.119 (0.528, 8.501) | 0.289 |
| Lip, NOS | 0.776 (0.249, 2.414) | 0.661 |
| Lung, lower lobe | 1.867 (1.695, 2.056) | *<0.001* |
| Lung, middle lobe | 1.818 (1.645, 2.01) | *<0.001* |
| Lung, NOS | 2.072 (1.881, 2.282) | *<0.001* |
| Lung, overlapping | 2.044 (1.835, 2.276) | *<0.001* |
| Lung, upper lobe | 1.804 (1.639, 1.986) | *<0.001* |
| Myometrium | 2.321 (1.1, 4.898) | 0.027 |
| Pancreas, body | 2.771 (2.248, 3.416) | *<0.001* |
| Pancreas, head | 3.033 (2.606, 3.53) | *<0.001* |
| Pancreas, NOS | 3.769 (3.255, 4.365) | *<0.001* |
| Pancreas, other | 2.661 (1.499, 4.723) | *<0.001* |
| Pancreas, overlapping | 3.288 (2.553, 4.235) | *<0.001* |
| Pancreas, tail | 3.071 (2.573, 3.666) | *<0.001* |
| Pancreatic duct | 2.225 (0.313, 15.831) | 0.425 |
| Pylorus | 2.578 (0.963, 6.901) | 0.059 |
| Rectosigmoid junction | 1.694 (1.423, 2.016) | *<0.001* |
| Rectum, NOS | 1.516 (1.327, 1.732) | *<0.001* |
| Renal pelvis | 2.157 (1.698, 2.74) | *<0.001* |
| Skin, face other | 1.367 (1.087, 1.718) | 0.007 |
| Skin, lower limb | 1.257 (1.041, 1.517) | 0.017 |
| Skin, NOS | 1.485 (1.342, 1.643) | *<0.001* |
| Skin, overlapping | 3.934 (2.032, 7.613) | *<0.001* |
| Skin, scalp, and neck | 1.143 (0.944, 1.384) | *0.171* |
| Skin, trunk | 1.532 (1.344, 1.746) | *<0.001* |
| Skin, upper limb | 1.439 (1.218, 1.701) | *<0.001* |
| Stomach, body | 3.409 (2.536, 4.583) | *<0.001* |
| Stomach, fundus | 4.117 (2.858, 5.929) | *<0.001* |
| Stomach, greater curvature NOS | 2.157 (1.392, 3.344) | *<0.001* |
| Stomach, lesser curvature NOS | 1.896 (1.197, 3.003) | 0.006 |
| Stomach, NOS | 2.691 (2.24, 3.233) | *<0.001* |
| Stomach, overlapping | 4.853 (3.521, 6.688) | *<0.001* |
| Uterus, NOS | 1.979 (1.61, 2.433) | *<0.001* |

|  |  |  |
| --- | --- | --- |
| **Multivariate Cox Regression Using the 17 Important Predictors from Feature Selection**  **(Total Number = 145,429; No. of Events = 127,956)** | | |
| **Variable** | **Adjusted HR (95% CI)** | ***p-value*** |
| **Topography** |  |  |
| Anus | 2.304 (1.638, 3.241) | *<0.001* |
| Biliary | 2.57 (1.976, 3.343) | *<0.001* |
| Bone/joint | 1.568 (1.022, 2.405) | *0.04* |
| Breast | 1.72 (1.526, 1.939) | *<0.001* |
| Cervix | 3.599 (3.054, 4.242) | *<0.001* |
| Colon | 2.398 (2.143, 2.684) | *<0.001* |
| Digestive, other | 2.479 (2.115, 2.905) | *<0.001* |
| Esophagus | 2.705 (2.41, 3.036) | *<0.001* |
| Female genitals/placenta | 2.02 (1.451, 2.812) | *<0.001* |
| Gallbladder | 2.992 (2.286, 3.916) | *<0.001* |
| Kidney | 2.501 (2.18, 2.87) | *<0.001* |
| Liver | 2.927 (2.218, 3.864) | *<0.001* |
| Lung, non-small cell | 2.306 (2.077, 2.561) | *<0.001* |
| Lung, other | 2.668 (2.374, 2.999) | *<0.001* |
| Lung, small cell | 2.146 (1.787, 2.578) | *<0.001* |
| Melanoma | 2.482 (1.925, 3.202) | *<0.001* |
| Nasal | 1.663 (1.318, 2.098) | *<0.001* |
| NHL, extranodal | 4.353 (0.951, 19.917) | *0.058* |
| NHL, nodal | 4.939 (1.093, 22.316) | *0.038* |
| Ovary | 2.653 (2.18, 3.228) | *<0.001* |
| Pancreas | 3.153 (2.789, 3.565) | *<0.001* |
| Skin, other | 1.763 (1.207, 2.575) | *0.003* |
| Small Intestine | 2.209 (1.773, 2.751) | *<0.001* |
| Soft Tissues | 2.213 (1.803, 2.715) | *<0.001* |
| Stomach | 2.668 (2.349, 3.03) | *<0.001* |
| Testis | 1.406 (0.929, 2.128) | *0.107* |
| Trachea/Larynx/Mediastinum | 1.935 (1.43, 2.618) | *<0.001* |
| Urinary tracts | 3.012 (2.269, 3.999) | *<0.001* |
| Urinary Bladder | 2.838 (2.354, 3.422) | *<0.001* |
| Uterus | 3.071 (2.64, 3.571) | *<0.001* |
| **Age** | 1.012 (1.011, 1.012) | *<0.001* |
| **Sex—Male** | 1.125 (1.113, 1.138) | *<0.001* |
| **Race** |  |  |
| American Indian | 1.088 (0.984, 1.204) | *0.1* |
| Asian | 0.798 (0.767, 0.83) | *<0.001* |
| Other | 0.82 (0.761, 0.883) | *<0.001* |
| Pacific Islander | 0.897 (0.787, 1.023) | *0.104* |
| Unknown | 0.837 (0.782, 0.896) | *<0.001* |
| White | 1.078 (1.058, 1.098) | *<0.001* |
| **Median Income adjusted in 2016** |  |  |
| Below $30,000 | 1.073 (0.951, 1.211) | *0.251* |
| $30,000 to $34,999 | 1.032 (0.914, 1.164) | *0.611* |
| $35,000 to $45,999 | 0.997 (0.884, 1.125) | *0.964* |
| Above $46,000 | 0.905 (0.802, 1.022) | *0.107* |
| **High school degree against 2016** |  |  |
| Less 6.3% | 1.058 (0.926, 1.208) | *0.41* |
| 6.3% to 10.8% | 1.062 (0.929, 1.213) | *0.378* |
| 10.9% to 17.6% | 1.031 (0.902, 1.178) | *0.654* |
| Above 17.6% | 0.949 (0.83, 1.084) | *0.437* |
| **Urban or Rural area (2013)** |  |  |
| Metro | 1.056 (1.018, 1.095) | *0.003* |
| Urban | 1.097 (1.041, 1.156) | *<0.001* |
| Rural | 1.101 (1.06, 1.144) | *<0.001* |
| **Facility Type** |  |  |
| Academic Cancer Program | 0.896 (0.85, 0.946) | *<0.001* |
| Community Cancer Program | 1.051 (0.993, 1.112) | *0.088* |
| Comprehensive Community Cancer Program | 1.03 (0.976, 1.086) | *0.288* |
| Integrated Cancer Program | 1.02 (0.966, 1.077) | *0.471* |
| **Morphology** |  |  |
| Acinar cell carcinoma | 1.947 (1.081, 3.507) | *0.026* |
| Acinar cell cystadenocarcinoma | 5.357 (0.693, 41.438) | *0.108* |
| Adenocarcinomas, other | 2.609 (1.464, 4.649) | *0.001* |
| Adenosquamous carcinoma | 3.153 (1.764, 5.636) | *<0.001* |
| Adnexal and skin appendage neoplasms | 3.118 (1.44, 6.753) | *0.006* |
| Atypical carcinoid tumor | 1.869 (0.999, 3.498) | *0.05* |
| Basal cell carcinomas, other | 17.233 (2.234, 132.915) | *0.006* |
| Basaloid squamous cell carcinoma | 2.811 (1.513, 5.222) | *0.001* |
| Blood vessel tumors, other | 1.43 (0.579, 3.531) | *0.438* |
| Carcinoid tumor, NOS | 1.414 (0.769, 2.601) | *0.265* |
| Carcinoma, other | 3.057 (1.716, 5.447) | *<0.001* |
| Carcinoma, undifferentiated, NOS | 3.736 (2.005, 6.959) | *<0.001* |
| Carcinosarcoma, NOS | 3.489 (1.893, 6.43) | *<0.001* |
| Cholangiocarcinoma | 2.934 (1.546, 5.566) | *<0.001* |
| Clear cell adenocarcinoma, NOS | 2.178 (1.213, 3.912) | *0.009* |
| CNS embryonal tumor, NOS | 11.237 (2.5, 50.496) | *0.002* |
| Combined small cell carcinoma | 3.092 (1.687, 5.665) | *<0.001* |
| Complex epithelial neoplasms | 3.889 (1.962, 7.708) | *<0.001* |
| Complex mixed and stromal neoplasms | 3.589 (1.889, 6.818) | *<0.001* |
| Cystic, mucinous, and serous carcinomas | 1.787 (0.887, 3.601) | *0.104* |
| Ductal and lobular carcinomas, other | 3.569 (1.851, 6.881) | *<0.001* |
| Endometrioid adenocarcinoma, NOS | 2.826 (1.551, 5.149) | *<0.001* |
| Ewing sarcoma | 4.611 (2.186, 9.725) | *<0.001* |
| Fibroepithelial neoplasms | 8.422 (2.695, 26.314) | *<0.001* |
| Fibromatous neoplasms | 3.131 (1.559, 6.29) | *0.001* |
| Germ cell neoplasms | 4.527 (1.828, 11.21) | *0.001* |
| Giant cell tumors | 9.102 (1.918, 43.201) | *0.005* |
| Granular cell tumors and alveolar soft part sarcomas | 1.706 (0.748, 3.892) | *0.204* |
| Hemangiosarcoma | 4.28 (2.28, 8.032) | *<0.001* |
| Hepatocellular carcinoma | 2.955 (1.558, 5.604) | *<0.001* |
| Hepatoid adenocarcinoma | 3.151 (1.597, 6.217) | *<0.001* |
| Infiltrating duct and lobular carcinoma | 2.572 (1.402, 4.716) | *0.006* |
| Infiltrating duct carcinoma, NOS | 3.048 (1.705, 5.449) | *<0.001* |
| Infiltrating duct mixed with other types of carcinoma | 2.421 (1.292, 4.538) | *0.006* |
| Inflammatory carcinoma | 3.679 (1.98, 6.839) | *<0.001* |
| Large cell carcinoma, NOS | 3.37 (1.884, 6.028) | *<0.001* |
| Large cell neuroendocrine carcinoma | 2.952 (1.652, 5.275) | *<0.001* |
| Leiomyosarcoma, NOS | 2.592 (1.385, 4.849) | *0.003* |
| Lepidic adenocarcinoma | 2.273 (1.254, 4.121) | *0.007* |
| Leukemias, other | 0.344 (0.067, 1.778) | *0.203* |
| Lipomatous sarcomas | 3.94 (1.801, 8.621) | *<0.001* |
| Lobular carcinoma, NOS | 3.066 (1.697, 5.537) | *<0.001* |
| Lymphoid leukemias | 1.537 (0.281, 8.421) | *0.62* |
| Malignant lymphoma, diffuse | 0.746 (0.161, 3.456) | *0.708* |
| Malignant lymphoma, large B-cell, diffuse, NOS | 1.09 (0.269, 4.407) | *0.904* |
| Malignant lymphoma, non-Hodgkin, NOS | 0.636 (0.147, 2.754) | *0.545* |
| Malignant melanoma, NOS | 1.98 (1.064, 3.686) | *0.031* |
| Malignant peripheral nerve sheath tumor | 4.39 (2.068, 9.321) | *<0.001* |
| Malignant tumor, NOS | 2.774 (1.325, 5.808) | *0.007* |
| Mature B-cell lymphomas, other | 0.496 (0.118, 2.084) | *0.339* |
| Mature T- and NK-cell lymphomas | 1.383 (0.323, 5.921) | *0.662* |
| Melanoma, other | 2.04 (1.073, 3.88) | *0.03* |
| Miscellaneous tumors, other | 2.043 (0.436, 9.576) | *0.364* |
| Mixed cell adenocarcinoma | 2.19 (1.148, 4.176) | *0.017* |
| Mucin-producing adenocarcinoma | 2.495 (1.375, 4.528) | *0.003* |
| Mucinous adenocarcinoma | 2.763 (1.544, 4.945) | *<0.001* |
| Mucoepidermoid carcinoma | 2.996 (1.373, 6.536) | *0.006* |
| Mullerian mixed tumor | 2.931 (1.467, 5.856) | *0.002* |
| Myomatous neoplasms, other | 5.054 (2.528, 10.106) | *<0.001* |
| Myxomatous neoplasms | 0.52 (0.067, 4.045) | *0.532* |
| Neoplasm, malignant | 3.733 (2.094, 6.655) | *<0.001* |
| Neuroendocrine carcinoma, NOS | 2.754 (1.543, 4.914) | *<0.001* |
| Neuroepitheliomatous neoplasms | 1.681 (0.613, 4.606) | *0.313* |
| Nodular melanoma | 2.878 (1.524, 5.434) | *0.001* |
| Non-small cell carcinoma | 3.204 (1.797, 5.713) | *<0.001* |
| Oat cell carcinoma | 3.442 (1.83, 6.476) | *<0.001* |
| Osseous and chondromatous neoplasms | 4.395 (2.084, 9.266) | *<0.001* |
| Papillary adenocarcinoma, NOS | 2.022 (1.127, 3.626) | *0.018* |
| Papillary carcinoma, NOS | 2.601 (1.361, 4.968) | *0.004* |
| Papillary transitional cell carcinoma | 2.603 (1.385, 4.893) | *0.003* |
| Paragangliomas and glomus tumors | 0.559 (0.072, 4.34) | *0.578* |
| Plasma cell tumors | Na | *NA* |
| Pleomorphic carcinoma | 3.104 (1.683, 5.727) | *<0.001* |
| Pseudosarcomatous carcinoma | 3.857 (2.147, 6.929) | *<0.001* |
| Renal cell carcinoma, NOS | 2.475 (1.378, 4.446) | *0.002* |
| Renal cell carcinoma, other | 2.739 (1.265, 5.933) | *0.011* |
| Renal cell carcinoma, sarcomatoid | 4.176 (2.276, 7.659) | *<0.001* |
| Serous carcinoma, NOS | 2.597 (1.371, 4.918) | *0.003* |
| Signet ring cell carcinoma | 3.258 (1.812, 5.858) | *<0.001* |
| Small cell carcinoma, intermediate cell | 2.851 (1.412, 5.753) | *0.006* |
| Small cell carcinoma, NOS | 3.328 (1.833, 6.042) | *<0.001* |
| Soft tissue sarcomas, NOS | 3.549 (1.942, 6.486) | *<0.001* |
| Solid carcinoma, NOS | 2.112 (1.131, 3.946) | *0.019* |
| Specialized gonadal neoplasms | 28.818 (3.707, 224.049) | *0.001* |
| Spindle cell carcinoma, NOS | 5.589 (2.992, 10.438) | *<0.001* |
| Spindle cell melanoma, NOS | 1.727 (0.857, 3.479) | *0.127* |
| Spindle cell sarcoma | 5.01 (2.532, 9.912) | *<0.001* |
| Squamous cell carcinoma, keratinizing, NOS | 3.387 (1.885, 6.085) | *<0.001* |
| Squamous cell carcinoma, large cell, nonkeratinizing, NOS | 3.057 (1.691, 5.527) | *<0.001* |
| Squamous cell carcinoma, NOS | 3.285 (1.843, 5.856) | *<0.001* |
| Squamous cell carcinoma, spindle cell | 3.744 (1.919, 7.306) | *<0.001* |
| Squamous cell neoplasms, other | 3.694 (1.872, 7.29) | *<0.001* |
| Struma ovarii, malignant | 3.808 (1.936, 7.49) | *<0.001* |
| Synovial sarcomas | 6.35 (2.992, 13.479) | *<0.001* |
| Thymic epithelial neoplasms | 12.014 (1.557, 92.724) | *0.017* |
| Transitional cell carcinomas, other | 3.172 (1.746, 5.762) | *<0.001* |
| Trophoblastic neoplasms, other | 1.927 (0.545, 6.816) | *0.309* |
| **Great circle distance in miles** | 1 (1, 1) | *<0.001* |
| **Total Charlson-Deyo Score** |  |  |
| 1 | 1.138 (1.123, 1.153) | *<0.001* |
| 2 | 1.204 (1.18, 1.229) | *<0.001* |
| 3 | 1.306 (1.272, 1.342) | *<0.001* |
| **Coexisting Liver Metastases** |  |  |
| Not applicable | 1.108 (0.818, 1.502) | *0.66* |
| Unknown | 1.088 (1.044, 1.134) | *<0.001* |
| Yes | 1.536 (1.515, 1.557) | *<0.001* |
| **Summary of Surgical Margins (surgery at primary site)** |  |  |
| Margins not evaluable | 0.939 (0.777, 1.134) | *0.513* |
| Microscopic residual | 0.798 (0.657, 0.969) | *0.022* |
| No primary site surgery | 1.112 (0.939, 1.316) | *0.218* |
| No residual margins | 0.565 (0.476, 0.671) | *<0.001* |
| Residual, NOS | 0.89 (0.74, 1.071) | *0.217* |
| Unknown | 0.736 (0.613, 0.883) | *<0.001* |
| **Summary of Chemotherapy** |  |  |
| Contraindicated | 2.772 (2.696, 2.849) | *<0.001* |
| Not administered | 2.067 (2.016, 2.119) | *<0.001* |
| Not administered, patient died | 5.736 (5.559, 5.919) | *<0.001* |
| Not a part of the first course of treatment | 2.014 (1.986, 2.042) | *<0.001* |
| Unknown | 1.261 (1.214, 1.309) | *<0.001* |
| **Summary of Hormone Therapy** |  |  |
| Contraindicated | 1.736 (1.623, 1.856) | *<0.001* |
| Not administered | 1.721 (1.639, 1.808) | *<0.001* |
| Not administered, patient died | 3.003 (2.534, 3.559) | *<0.001* |
| Not a part of the first course of treatment | 1.363 (1.309, 1.419) | *<0.001* |
| Unknown | 1.697 (1.598, 1.801) | *<0.001* |
| **Summary of Immunotherapy** |  |  |
| Contraindicated | 1.777 (1.577, 2.002) | *<0.001* |
| Not administered | 1.616 (1.435, 1.819) | *<0.001* |
| Not administered, patient died | 2.711 (2.364, 3.109) | *<0.001* |
| Not a part of the first course of treatment | 1.85 (1.805, 1.897) | *<0.001* |
| Unknown | 1.162 (1.03, 1.311) | *<0.001* |
| **Summary of Radiation Therapy** |  |  |
| Contraindicated | 1.574 (1.491, 1.662) | *<0.001* |
| Not administered | 1.217 (1.177, 1.26) | *<0.001* |
| Not administered, patient died | 1.854 (1.606, 2.14) | *<0.001* |
| Not a part of the first course of treatment | 1.183 (1.166, 1.2) | *<0.001* |
| Unknown | 1.159 (1.122, 1.198) | *<0.001* |

Chart, scatter chart

Description automatically generated

Chart

Description automatically generated

Graphical user interface, application


Description automatically generated

Chart, line chart

Description automatically generated

Graphical user interface, application

Description automatically generated



Graphical user interface

Description automatically generated